1. De novo kidney graft tumors: results from a multicentric retrospective national study
- Author
-
Tillou, X., Doerfler, A., Collon, S., Kleinclauss, F., Patard, J.-J., Badet, L., Barrou, B., Audet, M., Bensadoun, H., Berthoux, E., Bigot, P., Boutin, J.-M., Bouzguenda, Y., Chambade, D., Codas, R., Dantal, J., Deturmeny, J., Devonec, M., Dugardin, F., Ferrière, J.-M., Erauso, A., Feuillu, B., Gigante, M., Guy, L., Karam, G., Lebret, T., Neuzillet, Y., Legendre, C., Perez, T., Rerolle, Jean-Philippe, Salomon, L., Sallusto, F., Sénéchal, C., Terrier, N., Thuret, R., Verhoest, G., Petit, J., Renseigné, Non, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Department of Civil Engineering [Lebanese American University] (CE/SOE/LAU), School of Engineering [Lebanese American University] (SOE/LAU), Lebanese American University (LAU)-Lebanese American University (LAU), Domaines Océaniques (LDO), Institut national des sciences de l'Univers (INSU - CNRS)-Université de Brest (UBO)-Observatoire des Sciences de l'Univers-Institut d'écologie et environnement-Centre National de la Recherche Scientifique (CNRS), Department of Environmental Science [Philippines], Ateneo de Manila University, Pharmacologie des Immunosuppresseurs et de la Transplantation (PIST), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Clinique d'urologie, and CHU Grenoble
- Subjects
Male ,MESH: Carcinoma, Papillary ,medicine.medical_treatment ,030232 urology & nephrology ,MESH: Kidney Transplantation ,0302 clinical medicine ,MESH: Aged, 80 and over ,Immunology and Allergy ,Pharmacology (medical) ,MESH: Incidence ,Kidney transplantation ,MESH: Aged ,Aged, 80 and over ,Kidney ,MESH: Middle Aged ,Incidence ,MESH: Carcinoma, Renal Cell ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,Middle Aged ,Prognosis ,Nephrectomy ,Kidney Neoplasms ,3. Good health ,Survival Rate ,medicine.anatomical_structure ,MESH: Young Adult ,030220 oncology & carcinogenesis ,Female ,France ,Adult ,medicine.medical_specialty ,MESH: Survival Rate ,Adolescent ,MESH: Prognosis ,03 medical and health sciences ,Young Adult ,medicine ,Carcinoma ,Humans ,Survival rate ,Carcinoma, Renal Cell ,Dialysis ,Aged ,Retrospective Studies ,MESH: Adolescent ,Transplantation ,MESH: Humans ,business.industry ,Retrospective cohort study ,MESH: Adult ,MESH: Retrospective Studies ,medicine.disease ,Kidney Transplantation ,MESH: Male ,Carcinoma, Papillary ,Surgery ,MESH: France ,MESH: Kidney Neoplasms ,business ,MESH: Female - Abstract
International audience; De novo tumors in renal allografts are rare and their prevalence is underestimated. We therefore analyzed renal cell carcinomas arising in renal allografts through a retrospective French renal transplant cohort. We performed a retrospective, multicentric survey by sending questionnaires to all French kidney transplantation centers. All graft tumors diagnosed after transplantation were considered as de novo tumors. Thirty-two centers participated in this study. Seventy-nine tumors were identified among 41 806 recipients (Incidence 0.19%). Patients were 54 men and 25 women with a mean age of 47 years old at the time of diagnosis. Mean tumor size was 27.8 mm. Seventy-four (93.6%), 53 (67%) and 44 tumors (55.6%) were organ confined (T1-2), low grade (G1-2) and papillary carcinomas, respectively. Four patients died of renal cell carcinomas (5%). The mean time lapse between transplantation and RCC diagnosis was 131.7 months. Thirty-five patients underwent conservative surgery by partial nephrectomy (n = 35, 44.3%) or radiofrequency (n = 5; 6.3%). The estimated 5 years cancer specific survival rate was 94%. Most of these tumors were small and incidental. Most tumors were papillary carcinoma, low stage and low grade carcinomas. Conservative treatment has been preferred each time it was feasible in order to avoid a return to dialysis.
- Published
- 2012